News

AB-Therapeutics to participate at the annual meeting of Association of Cancer Research (EACR) in Barcelona, Catalonia, Spain

During the congress the company will present new data with the compound ABTL0812, on the mechanism of action and preclinical efficacy in experimental models of lung and pancreas, as well as data on toxicology and pharmacokinetics.
The work presented has been selected by the evaluation committee of the EACR.

June 29, 2012

AB-Therapeutics, SL, pharmaceutical biotechnology company with a product in clinical phase planned for the first quarter of 2013, announced today that Jordi Espadaler, PhD, Senior Advisor, Discovery Research and co-founder, will participate in the Annual Meeting of the European Association of Cancer Research (AACR ) in Barcelona (July 7-10). Dr. Espadaler will present new data on the mechanism of action and preclinical efficacy in experimental models of lung and pancreas with the  compound ABTL0812, as well as data on toxicology and pharmacokinetics. The work presented has been selected by the evaluation committee of the EACR.

ABTL0812 presents significant advantages over conventional chemotherapy: very low toxicity, oral administration, and most importantly, high efficacy. The product affects two cellular processes related to cell division and thus the proliferation of cancer cells: a) synthesis of DNA through inhibition of the expression of the dihydrofolate reductase (DHFR) gene, and b) inhibiting mTOR pathway that is involved in protein synthesis. By blocking these two key cellular functions, tumor cells are killed by a mechanism called autophagy, in which cells digest themselves.

About AB Therapeutics, SL

AB Therapeutics, SL is a research and development biopharmaceutical company founded in 2009 with headquarters in Bellaterra (Barcelona), Catalonia, Spain, located at the campus of the Autonomous University of Barcelona and with facilities planned in Boston in the US for 2012.
 
AB Therapeutics, SL aims to develop safer human therapies, based on the modulation of the activity of cell-membranes to treat various cancers, especially those with high medical needs due to its high mortality. The firm has a molecule, ABTL0812, in regulatory preclinical development, Phase I clinical trials (First in Man) is planned for the third quarter of 2012. A second drug candidate, ABTL1014 will begin preclinical development during the last quarter of 2012.
 
Contact:

Press:
Nuria Peláez
Tel. +34 902 903 844
media.relations@ab-therapeutics.com
 www.ab-therapeutics.com

Investors:
Carles Domènech, PhD
Tel. +34 935 868 977
contact@ab-therapeutics.com
www.ab-therapeutics.com

LATEST NEWS

05.10.2017

News

Ability Pharmaceuticals announces the approval from the French Medicines Agency ANSM to initiate a Phase 1/2a Clinical Trial with ABTL0812 to treat patients with endometrial cancer or squamous lung cancer as first-line therapy in France + info
18.09.2017

News

Ability Pharmaceuticals Announces EMA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer + info
07.03.2017

News

Ability Pharma sponsors the 37th National Meeting of the Spanish Society of Pharmacology + info
20.02.2017

News

Ability Pharmaceuticals launches a new updated website with a fresh design + info
15.12.2016

News

Ability Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer + info
22.11.2016

News

Ability Pharmaceuticals Initiates Phase 2 Combination Trial with ABTL0812 as First Line Therapy in Patients with Endometrial or Squamous Lung Cancer Patients + info
11.05.2016

News

Ability Pharmaceuticals Enters into a Licensing Agreement with SciClone Pharmaceuticals for the Novel Anticancer Agent ABTL0812 for the China Market. + info
07.04.2015

News

Ability Pharmaceuticals Receives Positive Opinion from EMA for Orphan Drug Status of ABTL0812 in Pediatric Cancer Neuroblastoma. + info
14.02.2014

News

Ability Pharmaceuticals to Present at the 7th Annual European Life Sciences CEO Forum in Zurich, March 4-5, 2014. + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
Credits